Session Information
Date: Tuesday, June 21, 2016
Session Title: Therapy in movement disorders: Gene and cell-based therapies
Session Time: 12:30pm-2:00pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To describe the incidence and severity of infusion-related adverse events of mesenchymal stem cells (MSC) for Parkinson’s disease in patients who underwent treatment.
Background: Cell-based therapy has emerged as an innovative method of treatment for neurodegenerative diseases, including Parkinson’s disease. With their relative ease of expansion, and lack of significant immunogenicity, MSCs may be a potential treatment option for these patients.
Methods: Medical records of 11 previously diagnosed Parkinson’s disease patients who were given intravenous and/or intraspinal infusions of minimally manipulated autologous bone marrow-derived MSCs were reviewed. Demographic and clinical data were obtained. Any infusion-related adverse effects were reported.
Results: Patients received between 1and 10 monthly infusions, with a mean of 6 infusions. Out of 66 total infusions, there was only 1 recorded instance of adverse event reported by the patient as non-disabling cervical pain, relieved by oral pain medications. Intravenous and intraspinal infusions were performed with no noted technical difficulty. One patient expired 1 year after his last dose, due to complications of Parkinson’s disease not related to mesenchymal stem cell infusion.
Conclusions: Intravenous and/or intraspinal infusion of bone marrow-derived autologous MSC therapy for Parkinson’s disease is safe, and is not associated with any significant infusion-related mortality or morbidity.
To cite this abstract in AMA style:
M.J.O.V. Buensalido, J.J.A. Tiongson. A descriptive study on the safety and feasibility of mesenchymal stem cell therapy for Parkinson’s disease: A case series [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/a-descriptive-study-on-the-safety-and-feasibility-of-mesenchymal-stem-cell-therapy-for-parkinsons-disease-a-case-series/. Accessed November 1, 2024.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/a-descriptive-study-on-the-safety-and-feasibility-of-mesenchymal-stem-cell-therapy-for-parkinsons-disease-a-case-series/